Çalışmalarında, Benim de İçinde Bulunduğum Çalışmalardaki Sonuçları Kaynak Gösteren Yayınların Dökümü
1. Valle RF, Ekpo GE. Hysteroscopic Metroplasty for the Septate Uterus: Review and Meta-Analysis. Journal of Minimally Invasive Gynecology 2013; 20:22-42.
2. Mutlu MF, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, et al. Antral follicle count determines poor ovarian response better than anti-mullerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. Journal of Assisted Reproduction and Genetics 2013; 30:657-65.
3. Miles EL, O`Gorman C, Zhao JG, Samuel M, Walters E, Yi YJ, et al. Transgenic pig carrying green fluorescent proteasomes. Proceedings of the National Academy of Sciences of the United States of America 2013; 110:6334-39.
4. Kjerulff KH, Velott DL, Zhu JJ, Chuang CH, Hillemeier MM, Paul IM, et al. Mode of First Delivery and Women`s Intentions for Subsequent Childbearing: Findings from the First Baby Study. Paediatric and Perinatal Epidemiology 2013; 27:62-71.
5. Deb S, Campbell BK, Clewes JS, Pincott-Allen C, Raine-Fenning NJ. Intracycle variation in number of antral follicles stratified by size and in endocrine markers of ovarian reserve in women with normal ovulatory menstrual cycles. Ultrasound in Obstetrics & Gynecology 2013; 41:216-22.
6. Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clinical Endocrinology 2013; 78:379-84.
7. Zheng Y, Liu XS, Guo SW. Therapeutic potential of andrographolide for treating endometriosis. Human Reproduction 2012; 27:1300-13.
8. Yuan X, Lin HY, Wang Q, Li TC. Is premature ovarian ageing a cause of unexplained recurrent miscarriage? Journal of Obstetrics and Gynaecology 2012; 32:464-66.
9. Yaghjyan L, Mahoney MC, Succop P, Wones R, Buckholz J, Pinney SM. Relationship between breast cancer risk factors and mammographic breast density in the Fernald Community Cohort. British Journal of Cancer 2012; 106:996-1003.
10. Yaghjyan L, Colditz GA, Wolin K. Physical activity and mammographic breast density: a systematic review. Breast Cancer Research and Treatment 2012; 135:367-80.
11. Wolf J, Armstrong B. The Association of Season and Temperature with Adverse Pregnancy Outcome in Two German States, a Time-Series Analysis. Plos One 2012; 7.
12. Wiklund I, Andolf E, Lilja H, Hildingsson I. Indications for cesarean section on maternal request - Guidelines for counseling and treatment. Sexual & Reproductive Healthcare 2012; 3:99-106.
13. Wang YPA, Farquhar C, Sullivan EA. Donor age is a major determinant of success of oocyte donation/recipient programme. Human Reproduction 2012; 27:118-25.
14. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2012.
15. Soares SR, Martinez-Varea A, Hidalgo-Mora JJ, Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. Fertility and Sterility 2012; 98:529-55.
16. Simsek Y, Celik O, Karaer A, Gul M, Yilmaz E, Koc O, et al. Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Archives of Gynecology and Obstetrics 2012; 286:777-83.
17. Scheetz D, Folger JK, Smith GW, Ireland JJ. Granulosa cells are refractory to FSH action in individuals with a low antral follicle count. Reproduction Fertility and Development 2012; 24:327-36.
18. Practice Comm Amer Soc Reprod M. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility 2012; 98:1407-15.
19. Pereira G, Cook A, Haggar F, Bower C, Nassar N. Seasonal variation in fetal growth: accounting for sociodemographic, biological, and environmental exposures. American Journal of Obstetrics and Gynecology 2012; 206.
20. Nicandri KF, Hoeger K. Diagnosis and treatment of polycystic ovarian syndrome in adolescents. Current Opinion in Endocrinology Diabetes and Obesity 2012; 19:497-504.
21. Liu HY, Liao SX, Zhou SL, Zhang DY, Liu HN, Zhao XL, et al. Experimental endometriosis reduction in rats treated with pioglitazone. African Journal of Microbiology Research 2012; 6:2580-85.
22. Lee HJ, Lee JM, Chang Y, Woo ST. Ultrasmall superparamagnetic iron oxides enhanced MR imaging in rats with experimentally induced endometriosis. Magnetic Resonance Imaging 2012; 30:860-68.
23. Kaya MG, Calapkorur B, Karaca Z, Yildirim S, Celik A, Akpek M, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clinical Endocrinology 2012; 77:885-92.
24. Gonzalez-Ramos R, Rocco J, Rojas C, Sovino H, Poch A, Kohen P, et al. Physiologic activation of nuclear factor kappa-B in the endometrium during the menstrual cycle is altered in endometriosis patients. Fertility and Sterility 2012; 97:645-51.
25. Gonzalez-Ramos R, Defrere S, Devoto L. Nuclear factor-kappaB: a main regulator of inflammation and cell survival in endometriosis pathophysiology. Fertility and Sterility 2012; 98:520-28.
26. Dasgupta S, Sirisha PVS, Neelaveni K, Anuradha K, Sudhakar G, Reddy BM. Role of luteinizing hormone beta-subunit gene variants among South Indian women with polycystic ovary syndrome. Gene 2012; 494:51-56.
27. Chen JZJ, Sheehan PM, Brennecke SP, Keogh RJ. Vessel remodelling, pregnancy hormones and extravillous trophoblast function. Molecular and Cellular Endocrinology 2012; 349:138-44.
28. Celik O, Celik E, Turkcuoglu I, Yilmaz E, Simsek Y, Tiras B. Germline cells in ovarian surface epithelium of mammalians: a promising notion. Reproductive Biology and Endocrinology 2012; 10.
29. Bakalis SP, Poon LCY, Vayna AM, Pafilis I, Nicolaides KH. C-reactive protein at 11-13 weeks` gestation in spontaneous early preterm delivery. Journal of Maternal-Fetal & Neonatal Medicine 2012; 25:2475-78.
30. Zhang JJ, Xu ZM, Zhang CM, Dai HY, Ji XQ, Wang XF, et al. Pyrrolidine dithiocarbamate inhibits nuclear factor-kappa B pathway activation, and regulates adhesion, migration, invasion and apoptosis of endometriotic stromal cells. Molecular Human Reproduction 2011; 17:175-81.
31. Zhang JJ, Xu ZM, Chang H, Zhang CM, Dai HY, Ji XQ, et al. Pyrrolidine Dithiocarbamate Attenuates Nuclear Factor-kappa B Activation, Cyclooxygenase-2 Expression and Prostaglandin E-2 Production in Human Endometriotic Epithelial Cells. Gynecologic and Obstetric Investigation 2011; 72:163-68.
32. Walton KL, Makanji Y, Robertson DM, Harrison CA: THE SYNTHESIS AND SECRETION OF INHIBINS. In: Activins and Inhibins. Volume 85, edn. Edited by Litwack G; 2011: 149-84.
33. van Ravenswaaij R, Tesselaar-van der Goot M, de Wolf S, van Leeuwen-Spruijt M, Visser GHA, Schielen P. First-trimester serum PAPP-A and f beta-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome. Prenatal Diagnosis 2011; 31:50-57.
34. Tuuli MG, Odibo AO. The Role of Serum Markers and Uterine Artery Doppler in Identifying At-Risk Pregnancies. Clinics in Perinatology 2011; 38:1-+.
35. Tolikas A, Tsakos E, Gerou S, Prapas Y, Loufopoulos A. Anti-Mullerian hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles. Human Fertility 2011; 14:246-53.
36. Strand LB, Barnett AG, Tong SL. The influence of season and ambient temperature on birth outcomes: A review of the epidemiological literature. Environmental Research 2011; 111:451-62.
37. Strand LB, Barnett AG, Tong SL. Methodological challenges when estimating the effects of season and seasonal exposures on birth outcomes. Bmc Medical Research Methodology 2011; 11.
38. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, et al. Antimullerian Hormone as a Predictor of Natural Fecundability in Women Aged 30-42 Years. Obstetrics and Gynecology 2011; 117:798-804.
39. Salem W, Flynn P, Weaver A, Brost B. Fertility After Cesarean Delivery Among Somali-Born Women Resident in the USA. Journal of Immigrant and Minority Health 2011; 13:494-99.
40. Rosen MP, Johnstone E, Addauan-Andersen C, Cedars MI. A lower antral follicle count is associated with infertility. Fertility and Sterility 2011; 95:1950-U107.
41. Ricci AG, Olivares CN, Bilotas MA, Meresman GF, Baranao RI. Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis. Reproductive Sciences 2011; 18:614-22.
42. Pedrosa AC, Matias A. Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers. Journal of Perinatal Medicine 2011; 39:619-35.
43. Njor SH, Hallas J, Schwartz W, Lynge E, Pedersen AT. Type of hormone therapy and risk of misclassification at mammography screening. Menopause-the Journal of the North American Menopause Society 2011; 18:171-77.
44. Menon R, Torloni MR, Voltolini C, Torricelli M, Merialdi M, Betran AP, et al. Biomarkers of Spontaneous Preterm Birth: An Overview of The Literature in the Last Four Decades. Reproductive Sciences 2011; 18:1046-70.
45. Maher MA. Luteal phase support may improve pregnancy outcomes during intrauterine insemination cycles. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011; 157:57-62.
46. Laaidi M, Boumendil A, Tran TC, Kaba H, Rozenberg P, Aegerter P. Effects of meteorological conditions on pregnancy outcome: Literature review. Environnement Risques & Sante 2011; 10:128-41.
47. Kyrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC, et al. Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction 2011; 26:1020-24.
48. Kloosterboer HJ. Historical milestones in the development of tibolone (Livial (R)). Climacteric 2011; 14:609-21.
49. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Human Reproduction 2011; 26:191-201.
50. Grytten J, Monkerud L, Hagen TP, Sorensen R, Eskild A, Skau I. The impact of hospital revenue on the increase in Caesarean sections in Norway. A panel data analysis of hospitals 1976-2005. Bmc Health Services Research 2011; 11.
51. Goksedef BPC, Akbayir O, Baran SY, Turan GY, Batmaz GK, Guraslan H, et al. Atypical squamous cells of undetermined significance in postmenopausal women: a comparative retrospective analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011; 159:418-21.
52. Gode F, Karagoz C, Posaci C, Saatli B, Uysal D, Secil M, et al. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate. Archives of Gynecology and Obstetrics 2011; 284:923-29.
53. Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Annales De Biologie Clinique 2011; 69:257-71.
54. Ferraretti AP, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of `poor response` to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction 2011; 26:1616-24.
55. Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility 2011; 96:501-U351.
56. Defrere S, Gonzalez-Ramos R, Lousse JC, Colette S, Donnez O, Donnez J, et al. Insights into iron and nuclear factor-kappa B (NF-kappa B) involvement in chronic inflammatory processes in peritoneal endometriosis. Histology and Histopathology 2011; 26:1083-92.
57. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. Bjog-an International Journal of Obstetrics and Gynaecology 2011; 118:1042-54.
58. Calogero AE, Calabro V, Catanuso M, Condorelli RA, La Vignera S. Understanding polycystic ovarian syndrome pathogenesis: An updated of its genetic aspects. Journal of Endocrinological Investigation 2011; 34:630-44.
59. Brown ZA, Louwers YV, Fong SL, Valkenburg O, Birnie E, de Jong FH, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertility and Sterility 2011; 96:1259-65.
60. Aydin Y, Atis A, Uludag S, Tezer I, Sakiz D, Acar H, et al. Remission of Endometriosis by Hyperbaric Oxygen Treatment in Rats. Reproductive Sciences 2011; 18:941-47.
61. Atis A, Tandogan T, Aydin Y, Sen C, Turgay F, Eren N, et al. Late pregnancy associated plasma protein A levels decrease in preterm labor. Journal of Maternal-Fetal & Neonatal Medicine 2011; 24:923-27.
62. Aslan M, Celik O, Dogan DG, Tagluk ME, Ulas M, Aydin E. Spectral changes in electrical activity of pylorus due to L-NAME induced hypertrophic pyloric stenosis. Bratislava Medical Journal-Bratislavske Lekarske Listy 2011; 112:13-17.
63. Zhao M, Chang C, Liu Z, Chen LM, Chen Q. The level of vascular endothelial cell growth factor, nitric oxide, and endothelin-1 was correlated with ovarian volume or antral follicle counts: A potential predictor of pregnancy outcome in IVF. Growth Factors 2010; 28:299-305.
64. Zhao JZ, Lin JJ, Yang HY, Zhang W, Huang XF, Huang YP. Effects of Oral Contraceptives and Metformin on the Outcome of In Vitro Maturation in Infertile Women with Polycystic Ovary Syndrome. Journal of Womens Health 2010; 19:261-65.
65. Zhang JJ, Xu ZM, Dai HY, Ji XQ, Duan YY, Zhang CM, et al. Application of the nuclear factor-kappa B inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study. Fertility and Sterility 2010; 94:2942-44.
66. Younis JS, Jadaon J, Izhaki I, Haddad S, Radin O, Bar-Ami S, et al. A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. Fertility and Sterility 2010; 94:655-61.
67. Wei SQ, Fraser W, Luo ZC. Inflammatory Cytokines and Spontaneous Preterm Birth in Asymptomatic Women A Systematic Review. Obstetrics and Gynecology 2010; 116:393-401.
68. Vrontikis A, Chang PL, Peter K, Lindheim SR. Antral follice counts (AFC) predict ovarian response and pregnancy outcomes in oocyte donation cycles. Journal of Assisted Reproduction and Genetics 2010; 27:383-89.
69. van Disseldorp J, Lambalk CB, Kwee J, Looman CWN, Eijkemans MJC, Fauser BC, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Human Reproduction 2010; 25:221-27.
70. van den Berg MH, van Dulmen-den Broeder E, Overbeek A, Twisk JWR, Schats R, van Leeuwen FE, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Human Reproduction 2010; 25:1520-27.
71. Torche F, Corvalan A. Seasonality of Birth Weight in Chile: Environmental and Socioeconomic Factors. Annals of Epidemiology 2010; 20:818-26.
72. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2010.
73. Speroff L. A tender subject. Menopause-the Journal of the North American Menopause Society 2010; 17:445-49.
74. Sahu B, Oztutrk O, Serhal P, Jayaprakasan K. Do ovarian reserve tests predict miscarriage in women undergoing assisted reproduction treatment? European Journal of Obstetrics & Gynecology and Reproductive Biology 2010; 153:181-84.
75. Romualdi D, Giuliani M, Cristello F, Fulghesu AM, Selvaggi L, Lanzone A, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertility and Sterility 2010; 93:2303-10.
76. Pal L, Bevilacqua K, Santoro NF. Chronic psychosocial stressors are detrimental to ovarian reserve: a study of infertile women. Journal of Psychosomatic Obstetrics and Gynecology 2010; 31:130-38.
77. Ojaniemi M, Tapanainen P, Morin-Papunen L. Management of Polycystic Ovary Syndrome in Childhood and Adolescence. Hormone Research in Paediatrics 2010; 74:372-75.
78. Nagirnaja L, Rull K, Uuskula L, Hallast P, Grigorova M, Laan M. Genomics and genetics of gonadotropin beta-subunit genes: Unique FSHB and duplicated LHB/CGB loci. Molecular and Cellular Endocrinology 2010; 329:4-16.
79. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian Journal of Medical Research 2010; 131:743-60.
80. Menon R, Taylor RN, Fortunato SJ. Chorioamnionitis - A complex pathophysiologic syndrome. Placenta 2010; 31:113-20.
81. Martin LOM, Munoz EC, De Cupere F, Van Driessche E, Echemendia-Blanco D, Rodriguez JMM, et al. Bacterial contamination of boar semen affects the litter size. Animal Reproduction Science 2010; 120:95-104.
82. Liu B, Wang NN, Wang ZL, Hong SS, Li JT, Ding HJ, et al. Improved nude mouse models for green fluorescence human endometriosis. Journal of Obstetrics and Gynaecology Research 2010; 36:1214-21.
83. Lieng M, Istre O, Qvigstad E. Treatment of endometrial polyps: a systematic review. Acta Obstetricia Et Gynecologica Scandinavica 2010; 89:992-1002.
84. Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics 2010; 281:35-42.
85. Ilad RS, Fleming SD, Murphy CR, Fazleabas AT. Immunohistochemical study of the ubiquitin-nuclear factor-kappa B pathway in the endometrium of the baboon (Papio anubis) with and without endometriosis. Reproduction Fertility and Development 2010; 22:1118-30.
86. Hascalik S, Celik O, Tagluk ME, Yildirim A, Aydin NE. Effects of highly purified urinary FSH and human menopausal FSH on uterine myoelectrical dynamics. Molecular Human Reproduction 2010; 16:200-06.
87. Haadsma ML, Groen H, Mooij TM, Burger CW, Broekmans FJM, Lambalk CB, et al. Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation. Reproductive Biomedicine Online 2010; 20:191-200.
88. Gonzalez-Ramos R, Van Langendonckt A, Defrere S, Lousse JC, Colette S, Devoto L, et al. Involvement of the nuclear factor-kappa B pathway in the pathogenesis of endometriosis. Fertility and Sterility 2010; 94:1985-94.
89. Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining Biochemical and Ultrasonographic Markers in Predicting Preeclampsia: A Systematic Review. Clinical Chemistry 2010; 56:361-75.
90. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR. Comparison of effects of 3 mg drospirenone plus 20 mu g ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertility and Sterility 2010; 94:1793-98.
91. Ferte-Delbende C, Catteau-Jonard S, Barriere P, Dewailly D. Evaluation of the ovarian reserve. Journal De Gynecologie Obstetrique Et Biologie De La Reproduction 2010; 39:S27-S33.
92. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology 2010; 162:193-212.
93. Conserva V, Signaroldi M, Mastroianni C, Stampalija T, Ghisoni L, Ferrazzi E. Distinction between fetal growth restriction and small for gestational age newborn weight enhances the prognostic value of low PAPP-A in the first trimester. Prenatal Diagnosis 2010; 30:1007-09.
94. Celik O, Yesilada E, Hascalik S, Celik N, Sahin I, Keskin L, et al. Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. Reproductive Biomedicine Online 2010; 20:492-98.
95. Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecological Endocrinology 2010; 26:804-14.
96. Zaidi S, Usmani A, Shokh IS, Alam SE. Ovarian Reserve and BMI Between Fertile and Subfiertile Women. Jcpsp-Journal of the College of Physicians and Surgeons Pakistan 2009; 19:21-24.
97. Wang XL, Han SP, Dai HH, You ZX, Fu SL, Lu PH. NF-kappa B Decoy Oligonucleotides Suppress RANTES Expression and Monocyte Chemotactic Activity via NF-kappa B Inactivation in Stromal Cells of Ectopic Endometrium. Journal of Clinical Immunology 2009; 29:387-95.
98. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2009.
99. Studen KB, Prezelj J, Kocjan T, Pfeifer M. MECHANISMS OF CARDIOVASCULAR DISEASE RISKS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. Zdravniski Vestnik-Slovenian Medical Journal 2009; 78:129-35.
100. Steiner AZ. Clinical Implication of Ovarian Reserve Testing. Obstetrical & Gynecological Survey 2009; 64:120-28.
101. Shah SJ, Yu KH, Sangar V, Parry SI, Blair IA. Identification and Quantification of Preterm Birth Biomarkers in Human Cervicovaginal Fluid by Liquid Chromatography/Tandem Mass Spectrometry. Journal of Proteome Research 2009; 8:2407-17.
102. Prapas N, Karkanaki A, Prapas I, Kalogiannidis I, Katsikis I, Panidis D. Genetics of Polycystic Ovary Syndrome. Hippokratia 2009; 13:216-23.
103. Peng HY, Chen GD, Lee SD, Lai CY, Chiu CH, Cheng CL, et al. Neuroactive steroids inhibit spinal reflex potentiation by selectively enhancing specific spinal GABA(A) receptor subtypes. Pain 2009; 143:12-20.
104. Ozer KS, Erenus M, Yoldemir T. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor in postmenopausal women. Climacteric 2009; 12:66-71.
105. Metwally M, Amer S, Li TC, Ledger L. An RCT of metformin versus orlistat for the management of obese anovulatory women. Human Reproduction 2009; 24:966-75.
106. Melo MAB, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertility and Sterility 2009; 91:148-56.
107. Lee JY, Lee WJ, Hur SE, Lee CM, Sung YA, Chung HW. 111/121 diplotype of Calpain-10 is associated with the risk of polycystic ovary syndrome in Korean women. Fertility and Sterility 2009; 92:830-33.
108. Lambert-Messerlian GM, Palomaki GE, Neveux LM, Chien E, Friedman A, Rosene-Montella K, et al. Early onset preeclampsia and second trimester serum markers. Prenatal Diagnosis 2009; 29:1109-17.
109. Lain SJ, Algert CS, Tasevski V, Morris JM, Roberts CL. Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study. Bmc Medical Research Methodology 2009; 9.
110. Kjotrod SB, Sunde A, von During V, Carlsen SM. Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. Fertility and Sterility 2009; 91:500-08.
111. Kebapcilar L, Yuksel A, Bozkaya G, Taner CE, Kebapcilar AG, Bilgir O, et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European Journal of Medicine 2009; 4:423-27.
112. Kamata M, Suzuki A, Matsumoto Y, Togashi H, Otani K. Effect of month of birth on personality traits of healthy Japanese. European Psychiatry 2009; 24:86-90.
113. Janat-Amsbury MM, Gupta KM, Kablitz CD, Peterson CM. Drug delivery for in vitro fertilization: Rationale, current strategies and challenges. Advanced Drug Delivery Reviews 2009; 61:871-82.
114. Honest H, Forbes CA, Duree KH, Norman G, Duffy SB, Tsourapas A, et al. Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technology Assessment 2009; 13:1-+.
115. Hackett A, Stott T, Boddy L, Stratton G. Is Air Temperature at Birth Associated with Body Mass Index in 9-10 Year-Old Children? Ecology of Food and Nutrition 2009; 48:123-36.
116. Haadsma ML, Groen H, Fidler V, Seinen LHM, Broekmans FJM, Heineman MJ, et al. The predictive value of ovarian reserve tests for miscarriage in a population of subfertile ovulatory women. Human Reproduction 2009; 24:546-52.
117. Gupta S, Sharma D, Surti N, Kesavan S, Khanna P, Agarwal A. Ovarian reserve testing: systematic review of the literature. Archives of Medical Science 2009; 5:S143-S50.
118. Greydanus DE, Omar HA, Tsitsika AK, Patel DR. Menstrual Disorders in Adolescent Females: Current Concepts. Dm Disease-a-Month 2009; 55:45-113.
119. Gibreel A, Maheshwari A, Bhattacharya S, Johnson NP. Ultrasound tests of ovarian reserve; A systematic review of accuracy in predicting fertility outcomes. Human Fertility 2009; 12:95-106.
120. Erel CT, Senturk LM. The impact of body mass index on assisted reproduction. Current Opinion in Obstetrics & Gynecology 2009; 21:228-35.
121. Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obesity Reviews 2009; 10:431-41.
122. Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, et al. Improving the patient`s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Human Reproduction 2009; 24:764-74.
123. Dedeoglu EN, Erenus M, Yoruk P. Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertility and Sterility 2009; 91:425-31.
124. Debski R, Kotarski J, Paszkowski T, Pawelczyk L, Pertynski T, Spaczynski M, et al. The expert team of Polish Gynecological Society on the use of tibolone under menopause hormonal therapy. Przeglad Menopauzalny 2009; 8:1-5.
125. Cvek B. Combating endometriosis by blocking proteasome and nuclear factor-kappa B pathways. Human Reproduction 2009; 24:2967-67.
126. Chodick G, Flash S, Deoitch Y, Shalev V. Seasonality in Birth Weight: Review of Global Patterns and Potential Causes. Human Biology 2009; 81:463-77.
127. Celik O, Ugras M, Hascalik S, Aydin NE, Abbasov T. Enhanced endometrial response to a magnetic intrauterine device: A preliminary study. European Journal of Contraception and Reproductive Health Care 2009; 14:437-43.
128. Celik O. Reply: Combating endometriosis by blocking proteasome and nuclear factor-kappa B pathways. Human Reproduction 2009; 24:2967-68.
129. Buist DSM, Anderson ML, Reed SD, Bowles EJA, Fitzgibbons ED, Gandara JC, et al. Short-Term Hormone Therapy Suspension and Mammography Recall A Randomized Trial. Annals of Internal Medicine 2009; 150:752-W135.
130. Borna S, Mirzaie F, Abdollahi A. Mid-trimester amniotic fluid C-reactive protein, ferritin and lactate dehydrogenase concentrations and subsequent risk of spontaneous preterm labour. Australian & New Zealand Journal of Obstetrics & Gynaecology 2009; 49:400-03.
131. Barba M, Schunemann HJ, Sperati F, Akl EA, Musicco F, Guyatt G, et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clinical Endocrinology 2009; 70:661-70.
132. Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, et al. Criteria for Polycystic Ovarian Morphology in Polycystic Ovary Syndrome as a Function of Age. Journal of Clinical Endocrinology & Metabolism 2009; 94:4961-70.
133. Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH. Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis 2009; 29:753-60.
134. Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH. Maternal Serum Activin A at 11-13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Fetal Diagnosis and Therapy 2009; 25:320-27.
135. Yildiz BO. Oral contraceptives in polycystic ovary syndrome: Risk-benefit assessment. Seminars in Reproductive Medicine 2008; 26:111-20.
136. Wu J, Zhu YQ, Jiang YF, Cao YP. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology 2008; 24:392-98.
137. Westerveld HE, Hoogendoorn M, de Jong AWF, Goverde AJ, Fauser B, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights. Pharmacology & Therapeutics 2008; 119:223-41.
138. Wang YA, Healy D, Black D, Sullivan EA. Age-specific success rate for women undertaking their first assisted reproduction technology treatment using their own oocytes in Australia, 2002-2005. Human Reproduction 2008; 23:1633-38.
139. Verhagen TEM, Hendriks DJ, Bancsi L, Mol BWJ, Broekmans FJM. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Human Reproduction Update 2008; 14:95-100.
140. Urbanek M: Genetic analyses of polycystic ovary syndrome; 2008.
141. Tormala R, Appt S, Clarkson TB, Groop PH, Ronnback M, Ylikorkala O, et al. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation. Atherosclerosis 2008; 198:174-78.
142. Sun WJ, Stegmann BJ, Henne M, Cwherino WH, Segars JH. A new approach to ovarian reserve testing. Fertility and Sterility 2008; 90:2196-202.
143. Spencer CA, Allen VM, Flowerdew G, Dooley K, Dodds L. Low levels of maternal serum PAPP-A in early pregnancy and the risk of adverse outcomes. Prenatal Diagnosis 2008; 28:1029-36.
144. Simoni M, Tempfer CB, Destenaves B, Fauser B. Functional genetic polymorphisms and female reproductive disorders: Part I: polycystic ovary syndrome and ovarian response. Human Reproduction Update 2008; 14:459-84.
145. Saraswat L, Porter M, Bhattacharya S. Caesarean section and tubal infertility: is there an association? Reproductive Biomedicine Online 2008; 17:259-64.
146. Renoux C, Dell`Aniello S, Garbe E, Suissa S. Hormone replacement therapy use and the risk of stroke. Maturitas 2008; 61:305-09.
147. Norman RJ, Ruifrok AE, Moran LJ, Robker RL: Recommended therapies for metabolic defects in polycystic ovary syndrome; 2008.
148. Mikolajczyk RT, Stanford JB, Ecochard R. Multilevel model to assess sources of variation in follicular growth close to the time of ovulation in women with normal fertility: a multicenter observational study. Reproductive Biology and Endocrinology 2008; 6.
149. Menon R. Spontaneous preterm birth, a clinical dilemma: Etiologic, pathophysiologic and genetic heterogeneities and racial disparity. Acta Obstetricia Et Gynecologica Scandinavica 2008; 87:590-600.
150. Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology 2008; 199:596-609.
151. Li YF, Li Y, Lai QH, Zhang HW, Zhu GJ, Jin L, et al. Comparison between a GnRH Agonist and a GnRH Antagonist Protocol for the Same Patient Undergoing IVF. Journal of Huazhong University of Science and Technology-Medical Sciences 2008; 28:618-20.
152. Khairy M, Clough A, El-Toukhy T, Coomarasamy A, Khalaf Y. Antral follicle count at down-regulation and prediction of poor ovarian response. Reproductive Biomedicine Online 2008; 17:508-14.
153. Johansen OE, Qvigstad E. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. Advances in Therapy 2008; 25:525-51.
154. Jing Z, Liang-Zhi X, Tai-Xiang W, Ying T, Yu-Jian J. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: An updated systematic review. Gynecological Endocrinology 2008; 24:590-600.
155. Jayaprakasan K, Campbell B, Hopkisson J, Clewes J, Johnson I, Raine-Fenning N. Establishing the intercycle variability of three-dimensional ultrasonographic predictors of ovarian reserve. Fertility and Sterility 2008; 90:2126-32.
156. Henke A, Gromoll J. New insights into the evolution of chorionic gonadotrophin. Molecular and Cellular Endocrinology 2008; 291:11-19.
157. Hansen CA, Barnett AG, Pritchard G. The effect of ambient air pollution during early pregnancy on fetal ultrasonic measurements during mid-pregnancy. Environmental Health Perspectives 2008; 116:362-69.
158. Gul OB, Somunkiran A, Yucel O, Demirci F, Ozdemir I. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics 2008; 277:25-30.
159. Fauser B, Diedrich K, Devroey P, Grp EW. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Human Reproduction Update 2008; 14:1-14.
160. Erdem M, Erdem A, Guler I, Atmaca S. Role of antral follicle count in controlled ovarian hyperstimulation and intrauterine insemination cycles in patients with unexplained subfertility. Fertility and Sterility 2008; 90:360-66.
161. El-Toukhy T, Sunkara SK, Coomarasamy A, Grace J, Khalaf Y. Outpatient hysteroscopy and subsequent IVF cycle outcome: a systematic review and meta-analysis. Reproductive Biomedicine Online 2008; 16:712-19.
162. Eijsink JJH, van der Leeuw-Harmsen L, van der Linden PJQ. Pregnancy after Caesarean section: fewer or later? Human Reproduction 2008; 23:543-47.
163. Carranza-Lira S, Cuan-Martinez JR, Rosales-Ortiz S. Brachial artery responses in menopausal women using tibolone. International Journal of Gynecology & Obstetrics 2008; 101:43-46.
164. Brameld KJ, Dickinson JE, O`Leary P, Bower C, Goldblatt J, Hewitt B, et al. First trimester predictors of adverse pregnancy outcomes. Australian & New Zealand Journal of Obstetrics & Gynaecology 2008; 48:529-35.
165. Bethea SW, Nestler JE. Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance. Panminerva Medica 2008; 50:295-304.
166. Zaidi S, Usmani A, Shokh IS. Ovarian reserve and reproductive age. Pakistan Journal of Medical Sciences 2007; 23:449-53.
167. Yin J, Liu Y, Lv LQ, Wang DH, Gong C, Xiao W, et al. Expression of leptin long-form receptor mRNA in luteinized granulosa cells of obese women with polycystic ovary syndrome. Journal of Huazhong University of Science and Technology-Medical Sciences 2007; 27:461-63.
168. Wierik E, Hendricks PT, Martinez C. Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women. Menopause-the Journal of the North American Menopause Society 2007; 14:518-27.
169. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. Ppar Research 2007.
170. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends in Endocrinology and Metabolism 2007; 18:273-79.
171. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Critical Reviews in Clinical Laboratory Sciences 2007; 44:151-78.
172. Pillai AS, Bang H, Green C. Metformin & glitazones: Do they really help PCOS patients? Journal of Family Practice 2007; 56:444-53.
173. Nawrocka J, Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecological Endocrinology 2007; 23:231-37.
174. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Human Reproduction 2007; 22:317-22.
175. Muciaccia B, Corallini S, Vicini E, Padula F, Gandini L, Liuzzi G, et al. HIV-1 viral DNA is present in ejaculated abnormal spermatozoa of seropositive subjects. Human Reproduction 2007; 22:2868-78.
176. Mizejewski GJ. Physiology of alpha-fetoprotein as a biomarker for perinatal distress: Relevance to adverse pregnancy outcome. Experimental Biology and Medicine 2007; 232:993-1004.
177. Lorenz LB, Wild RA. Polycycstic ovarian syndrome: An evidence-based approach to evaluation and management of diabetes cardiovascular risks for today`s clinician. Clinical Obstetrics and Gynecology 2007; 50:226-43.
178. Lohsoonthorn V, Qiu CF, Williams MA. Maternal serum C-reactive protein concentrations in early pregnancy and subsequent risk of preterm delivery. Clinical Biochemistry 2007; 40:330-35.
179. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Mullerian hormone as a predictor of IVF outcome. Reproductive Biomedicine Online 2007; 14:602-10.
180. Ireland J, Ward F, Jimenez-Krassel F, Ireland JLH, Smith GW, Lonergan P, et al. Follicle numbers are highly repeatable within individual animals but are inversely correlated with FSH concentrations and the proportion of good-quality embryos after ovarian stimulation in cattle. Human Reproduction 2007; 22:1687-95.
181. Hendriks ML, Ket JCF, Hompes PGA, Homburg R, Lambalk CB. Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome. Human Reproduction Update 2007; 13:249-64.
182. Hendriks DJ, Kwee J, Mol BWJ, te Velde ER, Broekmans FJM. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertility and Sterility 2007; 87:764-75.
183. Haadsma ML, Bukman A, Groen H, Roeloffzen EMA, Groenewoud ER, Heineman MJ, et al. The number of small antral follicles (2-6 mm) determines the outcome of endocrine ovarian reserve tests in a subfertile population. Human Reproduction 2007; 22:1925-31.
184. Grisaru-Granovsky S, Halevy T, Planer D, Elstein D, Eidelman A, Samueloff A. PAPP-A levels as an early marker of idiopathic preterm birth: a pilot study. Journal of Perinatology 2007; 27:681-86.
185. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Human Reproduction Update 2007; 13:581-90.
186. Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clinical Obstetrics and Gynecology 2007; 50:205-25.
187. Dronavalli S, Ehrmann DA. Pharmacologic therapy of polycystic ovary syndrome. Clinical Obstetrics and Gynecology 2007; 50:244-54.
188. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2007.
189. Chodick G, Shalev V, Goren I, Inskip PD. Seasonality in birth weight in Israel: New evidence suggests several global patterns and different etiologies. Annals of Epidemiology 2007; 17:440-46.
190. Campisi R, Marengo FD. Cardiovascular effects of tibolone: A selective tissue estrogenic activity regulator. Cardiovascular Drug Reviews 2007; 25:132-45.
191. Birken S, McChesney R, Yershova O, Gaughan J, Pettersson K, Rechenberg G, et al. Patterns of LH beta cf among women in health and disease. Molecular and Cellular Endocrinology 2007; 260:172-82.
192. Bentley GR, Muttukrishna S. Potential use of biomarkers for analyzing interpopulation and cross-cultural variability in reproductive aging. Menopause-the Journal of the North American Menopause Society 2007; 14:668-79.
193. Batukan C, Muderris, II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecological Endocrinology 2007; 23:38-44.
194. Wang M, Ebmeier CC, Olin JR, Anderson RJ. Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs). Steroids 2006; 71:343-51.
195. Wald NJ, Morris JK, Ibison J, Wu TS, George LM. Screening in early pregnancy for pre-eclampsia using Down syndrome Quadruple test markers. Prenatal Diagnosis 2006; 26:559-64.
196. Topal NB, Ayhan S, Topal U, Bilgin T. Effects of hormone replacement therapy regimens on mammographic breast density: The role of progestins. Journal of Obstetrics and Gynaecology Research 2006; 32:305-08.
197. Teede HJ, Hutchison S, Zoungas S, Meyff C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 2006; 30:45-53.
198. T Sharma S, Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: Treatment with insulin sensitizers. Best Practice & Research Clinical Endocrinology & Metabolism 2006; 20:245-60.
199. Somunkiran A, Yazici B, Demirci F, Erdogmus B, Ozdemir I. Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause. Climacteric 2006; 9:59-65.
200. Patel SM, Nestler JE. Fertility in polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America 2006; 35:137-+.
201. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. European Journal of Endocrinology 2006; 154:763-75.
202. Noh JJ, Maskarinec G, Pagano I, Cheung LWK, Stanczyk FZ. Mammographic densities and circulating hormones: A cross-sectional study in premenopausal women. Breast 2006; 15:20-28.
203. Nogueira D, Friedler S, Schachter M, Raziel A, Ron-El R, Smitz J. Oocyte maturity and preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist or antagonist treatments. Fertility and Sterility 2006; 85:578-83.
204. Maheshwari A, Fowler P, Bhattacharya S. Assessment of ovarian reserve-should we perform tests of ovarian reserve routinely? Human Reproduction 2006; 21:2729-35.
205. Macklon NS, Stouffer RL, Giudice LC, Fauser B. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocrine Reviews 2006; 27:170-207.
206. Luque-Ramirez M, Millan JLS, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clinica Chimica Acta 2006; 366:14-26.
207. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Human Reproduction 2006; 21:121-28.
208. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. Journal of Clinical Endocrinology & Metabolism 2006; 91:1275-83.
209. Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006; 132:217-32.
210. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Human Reproduction Update 2006; 12:243-52.
211. Hyder SM. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocrine-Related Cancer 2006; 13:667-87.
212. Hart R, Norman R. Polycystic ovarian syndrome - prognosis and outcomes. Best Practice & Research in Clinical Obstetrics & Gynaecology 2006; 20:751-78.
213. Friedler S, Gilboa S, Schachter M, Raziel A, Strassburger D, El RR. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study. Reproductive Biomedicine Online 2006; 12:27-32.
214. Frattarelli JL. A prospective analysis of the changes in ovarian morphology during hormonal pituitary suppression before in vitro fertilization. Fertility and Sterility 2006; 86:577-82.
215. Erel CT, Senturk LM, Kaleli S. Tibolone and breast cancer. Postgraduate Medical Journal 2006; 82:658-62.
216. Elovitz MA, Mrinalini C. The use of progestational agents for preterm birth: Lessons from a mouse model. American Journal of Obstetrics and Gynecology 2006; 195:1004-10.
217. Diesch CH, Holzgreve W, Hahn S, Zhong XY. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenatal Diagnosis 2006; 26:1267-70.
218. Diaz-Garcia FJ, Herrera-Mendoza AP, Giono-Cerezo S, Guerra-Infante FM. Mycoplasma hominis attaches to and locates intracellularly in human spermatozoa. Human Reproduction 2006; 21:1591-98.
219. Crouchley K, Wylie E, Khong E. Hormone replacement therapy and mammographic screening outcomes in Western Australia. Journal of Medical Screening 2006; 13:93-97.
220. Cardona-Maya W, Lopez-Herrera A, Velilla-Hernandez P, Rugeles MT, Cadavid AP. The role of mannose receptor on HIV-1 entry into human spermatozoa. American Journal of Reproductive Immunology 2006; 55:241-45.
221. Bumsel F, Causse X, Bensouda-Grimaldi L, Megier P. Jaundice after induced ovulation by human recombinant follicle stimulating hormone (Gonal-f (R)). Gastroenterologie Clinique Et Biologique 2006; 30:1408-09.
222. Budak E, Sanchez MF, Bellver J, Cervero A, Simon C, Pellicer A. Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system. Fertility and Sterility 2006; 85:1563-81.
223. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproduction Update 2006; 12:685-718.
224. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxy-progesterone acetate on progression of carotid intima-media thickness: the osteoporosis prevention and arterial effects of tiboLone (OPAL) study. European Heart Journal 2006; 27:746-55.
225. Benton MJ. Osteoporosis: Recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. Journal of Community Health Nursing 2006; 23:201-11.
226. Beckers NGM, Platteau P, Eijkemans MJ, Macklon NS, de Jong FH, Devroey P, et al. The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women. European Journal of Endocrinology 2006; 155:355-63.
227. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Research 2006; 8.
228. Yaffe M, Hendrix S, Pike M, Santen R, Eden J, Genazzani AR. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer? Gynecological Endocrinology 2005; 21:17-21.
229. Vural F, Vural B, Yucesoy I. Reproductive aging and ovarian volume. International Journal of Gynecology & Obstetrics 2005; 91:73-74.
230. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Human Reproduction 2005; 20:2409-13.
231. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Human Reproduction Update 2005; 11:277-91.
232. Teede HJ, Meyer C, Norman RJ. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opinion on Pharmacotherapy 2005; 6:2419-27.
233. Speroff L. Clinical appraisal of the Women`s Health Initiative. Journal of Obstetrics and Gynaecology Research 2005; 31:80-93.
234. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology 2005; 152:269-75.
235. Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, et al. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: Effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Gynecological Endocrinology 2005; 20:144-49.
236. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Human Reproduction 2005; 20:1820-26.
237. Papageorghiou AT, Roberts N. Uterine artery Doppler screening for adverse pregnancy outcome. Current Opinion in Obstetrics & Gynecology 2005; 17:584-90.
238. Pabuccu R, Akar ME. Luteal phase support in assisted reproductive technology. Current Opinion in Obstetrics & Gynecology 2005; 17:277-81.
239. Obrzut B, Kuczynski W, Grygoruk C, Putowski L, Kluz S, Skret A. Liver dysfunction in severe ovarian hyperstimulation syndrome. Gynecological Endocrinology 2005; 21:45-49.
240. Ng EHY, Chan CCW, Tang OS, Ho PC. Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment. Human Reproduction 2005; 20:1647-54.
241. Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. European Journal of Obstetrics Gynecology and Reproductive Biology 2005; 118:209-13.
242. Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Bjog-an International Journal of Obstetrics and Gynaecology 2005; 112:228-33.
243. Koh KK, Han SH, Shin MS, Ahn JY, Lee Y, Shin EK. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. European Heart Journal 2005; 26:1362-68.
244. Junkermann H, von Holst T, Lang E, Rakov V. Influence of different HRT regimens on mammographic density. Maturitas 2005; 50:105-10.
245. Ibanez L, Jaramillo AM, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Human Reproduction 2005; 20:2457-62.
246. Ibanez L: Polycystic ovary syndrome (PCOS) in adolescence; 2005.
247. Hillard PJA. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinology and Metabolism Clinics of North America 2005; 34:707-+.
248. Harma M, Ozturk A. The effect of intranasal 17 beta-estradiol on mannnographic breast density. Maturitas 2005; 52:165-66.
249. Hahn S, Tan S, Elsenbruch S, Quadbeck B, Herrmann BL, Mann K, et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Hormone and Metabolic Research 2005; 37:438-44.
250. Friden B, Hreinsson J, Hovatta O. Birth of a healthy infant after in vitro oocyte maturation and ICSI in a woman with diminished ovarian response: Case report. Human Reproduction 2005; 20:2556-58.
251. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews 2005; 26:251-82.
252. Eden J. The need for tissue selective menopausal agents. Gynecological Endocrinology 2005; 21:22-27.
253. Cibula D, Fanta M, Vrbikova J, Stanicka S, Dvorakova K, Hill M, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction 2005; 20:180-84.
254. Boyanov MA, Shinkov AD. Effects of tibolone on body composition in postmenopausal women: a 1-year follow up study. Maturitas 2005; 51:363-69.
255. Bjarnson NH. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women. Danish Medical Bulletin 2005; 52:64-81.
256. Wierik E, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen plus progestogen therapies: a UK MediPlus (R) study. Climacteric 2004; 7:197-209.
257. Warren R. Hormones and mammographic breast density. Maturitas 2004; 49:67-78.
258. von Schoultz B. The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammographic density. Maturitas 2004; 49:S16-S21.
259. Verberckmoes S, Van Soom A, Kruif A. Intra-uterine insemination in farm animals and humans. Reproduction in Domestic Animals 2004; 39:195-204.
260. van Hooff MHA, Voorhorst FJ, Kaptein MBH, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Human Reproduction 2004; 19:383-92.
261. Valdivia I, Campodonico I, Tapia A, Capetillo M, Espinoza A, Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertility and Sterility 2004; 81:617-23.
262. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology 2004; 60:1-17.
263. Takahashi K, Karino K, Kanasakia H, Miyazakia K. Altered kinetics of pituitary response to gonadotropin-releasing hormone in women with variant luteinizing hormone: correlation with ovulatory disorders. Hormone Research 2004; 61:27-32.
264. Swegle JM, Kelly MW. Tibolone: A unique version of hormone replacement therapy. Annals of Pharmacotherapy 2004; 38:874-81.
265. Speroff L. Postmenopausal hormone therapy and breast cancer - A clinician`s message for patients. Endocrine 2004; 24:211-16.
266. Speroff L. A clinician`s review of the WHI-related literature. International Journal of Fertility and Womens Medicine 2004; 49:252-67.
267. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Garibaldi S, et al. Tibolone activates nitric oxide synthesis in human endothelial cells. Journal of Clinical Endocrinology & Metabolism 2004; 89:4594-600.
268. Sauer MV, Thornton MH, Schoolcraft W, Frishman GN. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online 2004; 9:487-93.
269. Santoro NF, Clarkson TB, Freedman RR, Fugh-Berman AJ, Loprinzi CL, Reame NK, et al. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause-the Journal of the North American Menopause Society 2004; 11:11-33.
270. Sahin I, Serter R, Karakurt F, Demirbas B, Culha C, Taskapan C, et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecological Endocrinology 2004; 19:115-24.
271. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: Opposite effects on adipocytokines and body adiposity. Journal of Clinical Endocrinology & Metabolism 2004; 89:1592-97.
272. Hahn S, Quadbeck B, Elsenbruch S, Gartner R, Finke R, Mann K, et al. Metformin, an efficacious drug in the treatment of polycystic ovary syndrome. Deutsche Medizinische Wochenschrift 2004; 129:1059-64.
273. Dubey RK, Gillespie DG, Grogli M, Kloosterboer HJ, Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: Role of estrogen, progesterone, and androgen receptors. Journal of Clinical Endocrinology & Metabolism 2004; 89:852-59.
274. Bukulmez O, Arici A. Luteal phase defect: myth or reality. Obstetrics and Gynecology Clinics of North America 2004; 31:727-+.
275. Bruce D, Robinson J, McWilliams S, Reddy M, Fentiman I, Rymer J. Long-term effects of tibolone on mammographic density. Fertility and Sterility 2004; 82:1343-47.
276. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 2004; 89:3835-40.
277. Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gomez MS, et al. Patients` and clinicians` attitudes after the Women`s Health Initiative study. Menopause-the Journal of the North American Menopause Society 2004; 11:57-61.
278. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: Experience with over 1000 consecutive patients. Journal of Clinical Endocrinology & Metabolism 2004; 89:453-62.
279. Anedda FM, Velati A, Lello S, Orru M, Paoletti AM, Melis GB, et al. Observational study on the efficacy of tibolone in counteracting early carotid atherosclerotic lesions in postmenopausal women. Hormone Research 2004; 61:47-52.
280. Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Practice & Research in Clinical Obstetrics & Gynaecology 2004; 18:707-18.
281. Yenen MC, Dede M, Goktolga U, Kucuk T, Pabuccu R. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. Climacteric 2003; 6:146-50.
282. Wei AY, Pritts EA. Therapy for polycystic ovarian syndrome. Current Opinion in Pharmacology 2003; 3:678-82.
283. Tsilchorozidou T, Prelevic GM. The role of metformin in the management of polycystic ovary syndrome. Current Opinion in Obstetrics & Gynecology 2003; 15:483-88.
284. Thompson WG, Bergstralh EJ, Slezak JM. Use of glucose, insulin, and C-reactive protein to determine need for glucose tolerance testing. Obesity Research 2003; 11:1027-32.
285. Senoh D, Tanaka H, Shiota A, Ohno M, Hata T. Laparoscopy-assisted intrapelvic sonography with a high-frequency, real-time miniature transducer to assess the ovary: A preliminary report. Gynecologic and Obstetric Investigation 2003; 55:162-67.
286. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy - Reply. British Medical Journal 2003; 326:1398-99.
287. Porcile A, Gallardo E, Duarte P, Aedo S. Effects on serum IGF-1 of tibolone (5 mg/day) vs combined continous estrogen/progestagen in post menopausal women. Revista Medica De Chile 2003; 131:1151-56.
288. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study. Journal of Clinical Endocrinology & Metabolism 2003; 88:148-56.
289. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 2003; 88:4649-54.
290. Ibanez L, de Zegher F. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Human Reproduction 2003; 18:57-60.
291. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 2003; 88:4116-23.
292. Fauser B, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends in Endocrinology and Metabolism 2003; 14:236-42.
293. Erel CT, Senturk LM, Kaleli S, Gezer A, Baysal B, Tasan E. Is serum leptin level regulated by thyroid functions, lipid metabolism and insulin resistance in polycystic ovary syndrome? Gynecological Endocrinology 2003; 17:223-29.
294. Elter K, Ay E, Erenus M. "Does birthweight affect the mode of delivery?" (vol 109, pg 138, 2003). European Journal of Obstetrics Gynecology and Reproductive Biology 2003; 111:221-21.
295. Dixon JM. Hormone replacement therapy and the breast. Surgical Oncology-Oxford 2003; 12:251-63.
296. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. Journal of Clinical Endocrinology & Metabolism 2003; 88:1927-32.
297. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocrine Reviews 2003; 24:633-67.
298. Christodoulakos GE, Lambrinoudaki IV, Panoulis KPC, Vourtsi AD, Vlachos L, Georgiou E, et al. The effect of various regimens of hormone replacement therapy on mammographic breast density. Maturitas 2003; 45:109-18.
299. Cagnacci A, Paoletti AM, Renzi A, Orru M, Pilloni M, Melis GB, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. Journal of Clinical Endocrinology & Metabolism 2003; 88:3621-25.
300. Bruni V, Dei M, Pontello V, Vangelisti P: The management of polycystic ovary syndrome. In: Women`s Health and Disease: Gynecologic and Reproductive Issues. Volume 997, edn. Edited by Creatsas G, Mastorakos G, Chrousos GP; 2003: 307-21.
301. Beckers NGM, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Journal of Clinical Endocrinology & Metabolism 2003; 88:4186-92.
302. Amarin ZO. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome - An aggressive, but perhaps life-saving procedure. Human Reproduction 2003; 18:659-64.
303. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause-the Journal of the North American Menopause Society 2003; 10:113-32.
304. Zoma WD, Baker RS, Kopernik G, Mershon JL, Clark KE. Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine. American Journal of Obstetrics and Gynecology 2002; 187:1555-60.
305. van de Ven J, Donker GH, Sprong M, Blankenstein MA, Thijssen JHH. Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 2002; 81:237-47.
306. Uncu G, Sozer MC, Develioglu O, Cengiz C. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS. Gynecological Endocrinology 2002; 16:447-52.
307. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002; 41:171-75.
308. Slanetz PJ. Hormone replacement therapy and breast tissue density on mammography. Menopause-the Journal of the North American Menopause Society 2002; 9:82-83.
309. Sills ES, Wittkowski KM, Tucker MJ, Perloe M, Kaplan CR, Palermo GD. Comparison of centrifugation- and noncentrifugation-based techniques for recovery of motile human sperm in assisted reproduction. Archives of Andrology 2002; 48:141-45.
310. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 2002; 5:390-98.
311. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. American Journal of Obstetrics and Gynecology 2002; 186:717-22.
312. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertility and Sterility 2002; 78:569-76.
313. Hacihanefioglu B, Somunkiran A, Mahmutoglu I, Sercelik A, Toptani S, Kervancioglu E. Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertility and Sterility 2002; 77:526-28.
314. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, et al. CAPN10 alleles are associated with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 2002; 87:3971-76.
315. Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertility and Sterility 2002; 78:351-59.
316. Geisthovel F. Functional hyperandrogenism (so-called "polycystic ovary syndrome"). New aspects of classification, etiology, diagnosis, and therapy. Gynakologe 2002; 35:48-63.
317. Gazvani R, Pakarinen P, Fowler P, Logan S, Huhtaniemi I. Lack of association of the common immunologically anomalous LH with endometriosis. Human Reproduction 2002; 17:1532-34.
318. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction 2002; 17:1729-37.
319. Deckers GH, Verheul HAM, van Aalst GBT, Cremers EAM, de Gooyer ME, Kloosterboer HJ. Tibolone and 5 alpha-dihydrotestosterone alone or in combination with an antiandrogen in a rat breast tumour model. European Journal of Cancer 2002; 38:443-48.
320. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KPC, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause-the Journal of the North American Menopause Society 2002; 9:110-16.
321. Takahashi K, Ozaki T, Kanasaki H, Miyazaki K. Successful pregnancy in a woman with ovarian failure associated with mutation in the beta-subunit of luteinizing hormone. Hormone Research 2001; 55:258-63.
322. Sendag F, Terek MC, Ozsener S, Oztekin K, Bilgin O, Bilgen I, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertility and Sterility 2001; 76:445-50.
323. Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. International Journal of Gynecology & Obstetrics 2001; 75:43-50.
324. Palacios S. Tibolone: what does tissue specific activity mean? Maturitas 2001; 37:159-65.
325. Palacios S. Tibolone: a tissue-specific approach to the menopause. European Heart Journal Supplements 2001; 3:M12-M16.
326. Norman RJ. Obesity, polycystic ovary syndrome and anovulation - how are they interrelated? Current Opinion in Obstetrics & Gynecology 2001; 13:323-27.
327. Lamminen T, Huhtaniemi I. A common genetic variant of luteinizing hormone; relation to normal and aberrant pituitary-gonadal function. European Journal of Pharmacology 2001; 414:1-7.
328. Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001; 40:151-57.
329. Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001; 40:165-71.
330. Doren M, Rubig A, Bennink H, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertility and Sterility 2001; 75:554-59.
331. Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heritability and heterogeneity. Human Reproduction Update 2001; 7:3-7.
332. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clinical Drug Investigation 2000; 20:101-07.
333. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: Elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocrine Reviews 2000; 21:551-83.
334. Palacios S: Tibolone: effects on the breast. In: Current Knowledge in Reproductive Medicine. Volume 1206, edn. Edited by Coutinho EM, Spinola P; 2000: 359-67.
335. Ortmann O, Schulz KD, Diedrich K. Hormone replacement therapy and risk of breast cancer. Gynakologe 2000; 33:402-07.
336. Kimmig R, Hillemanns P, Hepp H. Tibolone - an alternative to estrogen substitution. Gynakologe 2000; 33:408-15.
337. Ben-Rafael Z, Orvieto R. Polycystic ovary syndrome: a single gene mutation or an evolving set of symptoms. Current Opinion in Obstetrics & Gynecology 2000; 12:169-73.
338. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson K, Huhtaniemi I. Genetic variant of luteinizing hormone and risk of breast cancer in older women. Cancer Epidemiology Biomarkers & Prevention 2000; 9:839-42.
339. Ozdemir A, Konus O, Nas T, Erbas G, Cosar S, Isik S. Mammographic and ultrasonographic study of changes in the breast related to HRT. International Journal of Gynecology & Obstetrics 1999; 67:23-32.
340. Moore RA. Livial: a review of clinical studies. British Journal of Obstetrics and Gynaecology 1999; 106:1-21.
341. Egarter C. Hormonal treatment of postmenopausal patients with tibolone. Geburtshilfe Und Frauenheilkunde 1999; 59:282-88.
Diğer Kategoriler
